glp-1 agonists vs bariatric surgery weight loss comparison vs. Drugs | Garnet Health | Mid-Hudson Healthcare System The role of glucagon-like peptide-1

April 18, 2026 Drugs Consultative Committee 68th meeting flags surrogate advertising of GLP-1 obesity drugs state regulators directed to enforce Medical Dialogues March 24, 2026 CDSCO tightens checks on generic semaglutide bans promotional activity, intensifies pharmacy surveillance Business Standard March 21, 2026 Patent expiry Day 1 8+ manufacturers launch simultaneously, prices fall up to 90% from branded versions CNBC March 17, 2026 ZydusLupin and ZydusTorrent licensing agreements announced ahead of patent expiry Pearce IP February 2026 Natco Pharma receives CDSCO approval for generic semaglutide Eris Lifesciences to commercialise Fierce Pharma December 2025 Sun Pharma receives first DCGI approval for generic semaglutide in India Noveltreat and Sematrinity Sun Pharma PR REGULATORY FRAMEWORK CDSCO Standards & Approval Requirements in India India's Central Drugs Standard Control Organisation (CDSCO) is the national drug regulator equivalent to the US FDA

While real-world data on the level of adherence to dual GLP1-RA/GIP agonists are not available to date, some considerations can be drawn from available clinical trials and experiences with other pharmacological classes

Chatterjee, D

Over the past decade, studies have shown GLP-1 receptor agonists like semaglutide (Ozempic or Wegovy) reduce food seeking, but also alcohol intake, cocaine reward, nicotine self-administration, and relapse-like behavior spanning multiple drug classes

Endoscopic sleeve gastroplasty, for instance, is a relatively new procedure that does not require a surgeon to make incisions in the skin